PPC China

PPC China, now operating as Novotech, is a premier full-service Contract Research Organization (CRO) that provides end-to-end clinical development services across the Asia-Pacific region. Headquartered in Shanghai, the company specializes in Phase I-IV clinical trials, bioanalytical services, and regulatory consulting, with a particular focus on the Chinese market. In 2020, PPC Group merged with Novotech under the ownership of TPG Capital, creating a unified platform that is now one of the largest biotech-focused CROs in the region. The company is highly regarded for its ability to navigate the complex NMPA regulatory environment and its extensive network of clinical trial sites throughout mainland China. Its bioanalytical laboratories are GLP-compliant and support a wide range of therapeutic modalities, including small molecules and complex biologics. This strategic integration enables global biotechnology companies to execute seamless, high-quality clinical programs across multiple Asian geographies.